New Delhi, March 5 (IANS) Roche Pharma on Tuesday announced its foray into ophthalmology sector in India with a new bispecific monoclonal antibody (mAB) to treat vision loss.
Vabysmo (faricimab) may help in the treatment of neovascular or “wet” age-related macular degeneration (nAMD) and diabetic macular edema (DME) — the two leading causes of vision loss worldwide, said the company in a statement.
The world’s first bispecific mAB works by neutralising two key proteins — angiopoietin-2 (Ang-2) and vascular endothelial growth factor-A (VEGF-A) — known for the onset and progression of retinal conditions.
The proteins destabilise blood vessels in the eye, leading to inflammation and vision loss. Vabysmo may help block both pathways involving Ang-2 and VEGF-A and stabilise blood vessels.
“We believe more should be done to meet the needs of people living with retinal conditions and to preserve sight. While there is strong awareness and action for cataract and other frontal eye-disorders, retinal conditions are often diagnosed late or neglected, leading to vision loss,” said V Simpson Emmanuel, CEO and Managing Director, Roche Pharma India.
“The launch of Vabysmo marks our entry into the ophthalmology space in India, underscoring our commitment to bring the best-in-class innovations to the country. With fewer eye injections over time, while also improving and maintaining vision and anatomy, Vabysmo offers a more convenient and effective treatment schedule for patients, their caregivers and healthcare systems,” he added.
Currently available treatment options for nAMD and DME require frequent eye injections (typically every one to two months). With Vabysmo patients require eye injections at intervals of up to once in four months.
Vabysmo was first approved by the USFDA in January 2022, and is currently available in more than 90 countries.
–IANS
rvt/uk
Disclaimer
The information contained in this website is for general information purposes only. The information is provided by TodayIndia.news and while we endeavour to keep the information up to date and correct, we make no representations or warranties of any kind, express or implied, about the completeness, accuracy, reliability, suitability or availability with respect to the website or the information, products, services, or related graphics contained on the website for any purpose. Any reliance you place on such information is therefore strictly at your own risk.
In no event will we be liable for any loss or damage including without limitation, indirect or consequential loss or damage, or any loss or damage whatsoever arising from loss of data or profits arising out of, or in connection with, the use of this website.
Through this website you are able to link to other websites which are not under the control of TodayIndia.news We have no control over the nature, content and availability of those sites. The inclusion of any links does not necessarily imply a recommendation or endorse the views expressed within them.
Every effort is made to keep the website up and running smoothly. However, TodayIndia.news takes no responsibility for, and will not be liable for, the website being temporarily unavailable due to technical issues beyond our control.
For any legal details or query please visit original source link given with news or click on Go to Source.
Our translation service aims to offer the most accurate translation possible and we rarely experience any issues with news post. However, as the translation is carried out by third part tool there is a possibility for error to cause the occasional inaccuracy. We therefore require you to accept this disclaimer before confirming any translation news with us.
If you are not willing to accept this disclaimer then we recommend reading news post in its original language.
